Back to the future: Alzheimer's disease heterogeneity revisited
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The financial burden of caring for 5.2 million people with Alzheimer's disease (AD) is $214 billion. This number will rise to $1.2 trillion by 2050 if the projected tripling to 16 million cases does occur. Importantly, these estimates are likely to be conservative, given the numerous causes of dementia, underscoring the imperative for treatment. Furthermore, these numbers do not account for the emotional costs to patients and their families. Unfortunately, to date, there are no disease-modifying medications. The presumption of failed clinical trial studies is that intervention may be too late in the course of the disease 1. Thus, current research on AD includes significant effort to identify biomarkers decades before the threshold for clinical diagnosis is met 2. Most current biomarker studies focus on measures of β amyloid (Aβ) detected by positron emission tomography (PET) imaging or measured from cerebrospinal fluid 3-5. However, nearly 75% of cognitively normal individuals aged 70–79 years are free of significant amyloid on PET imaging 6. Furthermore, studies of younger individuals show differences in brain structure and cognitive ability related to APOE genotype status 7 or vascular risk factors 8 at a time when pathologic and in vivo measures of AD pathology are virtually absent. These data suggest that factors other than cerebral amyloidosis during early life may result in increased risk for later-life dementia. There is mounting evidence suggesting a more variable profile in which indices of the neurodegenerative processes (as indicated by changes in cognitive and brain structure) may precede amyloidosis 9. Despite results that challenge the Aβ model for AD pathogenesis, most clinical trial studies remain centered around amyloid as the primary target for drug development 10, 11. We propose that the reason clinical trial studies have largely failed is because the pharmaceutical and AD research communities assume AD is a single disease. In fact, it has been well documented that sporadic AD is a heterogeneous disease 12. Decades ago, the variability of the AD profile and its implication were more widely considered 13-15, but once the NINCDS-ADRDA diagnostic criteria was put into widespread practice, it was largely abandoned. This may be because the definite diagnosis of dementia depends on autopsy data, requiring widespread distribution of amyloid plaques and neurofibrillary tangles for diagnosis 16. Neuropathologic studies, however, suggest that other pathologies often co-occur and at times may lead to antemortem diagnosis of AD, even when neuropathologic criteria are not met 12. Consider now cancer as a model for rethinking the treatment strategy for AD. Like AD, cancer at its end stages is widespread and etiology is difficult to determine. Today, the diagnosis of cancer itself is uninformative. Rather research has determined that there are over 100 different types of cancers, identified in part by symptom variability. As a result of recognizing multiple forms of the disease, drug treatments target each type. Currently, a cancer diagnosis requires additional testing to pinpoint subtype and stage. Depending on the answer, different treatment options are considered. For the diagnosis of leukemia alone, there are over 70 treatment options. For AD, many different drug discovery studies are ongoing but there is no overt strategy of identifying the "types of AD" as potential targets for different drug treatment. Our analogy to cancer is not a clean one. Cancer is a different disease in which biopsy can differentiate between cancer cells and normal ones. The current work on AD biomarkers, however, is an equivalent attempt to find the earliest indicator of disease, similar to detecting preclinical cancer cells. Through biomarker research, the evidence suggests that there are people who are symptomatic for AD that have amyloid and those who do not. Furthermore, there are people without cognitive impairment who have amyloid and those who do not. On commonly used assessment methods, cognitive impairment profiles include those that are predominantly amnestic and those that are not. In fact, for almost every positive study in favor of a particular AD risk factor or biomarker, there are contradictory negative findings. Expression-based classification of patients into groups of interest has been a challenge due to patient heterogeneity. One potential solution to overcome some of these challenges has been to use prior knowledge in the form of information around known signaling pathways or protein-protein interaction networks into the statistical analysis procedure, resulting in a more integrated approach. The activity of these entire pathways or networks is then used, rather than the expression levels of single genes, to stratify patients into their respective groups. It has been shown in a number of studies that these approaches based on utilization of prior knowledge achieve better results (e.g. accuracy, reproduc
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Morris, J. C., Roe, C. M., Grant, E. A., Head, D., Storandt, M., Goate, A. M., Fagan, A. M., Holtzman, D. M., & Mintun, M. A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.269 · Cited by 476
Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome
Lam, B., Masellis, M., Freedman, M., Stuss, D. T., & Black, S. E. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt155 · Cited by 386 · cited 3×
“In fact, it has been well documented that sporadic AD is a heterogeneous disease [12].”
BackgroundInfluentialVasas, V., Fernando, C., Santos, M., Kauffman, S., & Szathmáry, E. (2012) · Biology Direct · doi:10.1186/1745-6150-7-1 · Cited by 369
Preclinical Alzheimer disease—the challenges ahead
Sperling, R. A., Karlawish, J., & Johnson, K. A. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.241 · Cited by 291 · cited 2×
“[1] Sperling RA, Karlawish J, Johnson KA.”
Background
Cited by
Santos, C. Y., Snyder, P. J., Wu, W., Zhang, M., Echeverria, A., & Alber, J. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.01.005 · Cited by 431
“The remarkable heterogeneity of risk factors, etiologies, and neuropathologic processes associated with AD makes it especially challenging for development of new treatments to slow disease progression [4,6].”
BackgroundGene-environment interactions in Alzheimer's disease: A potential path to precision medicine
Eid, A., Mhatre, I., & Richardson, J. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.005 · Cited by 164
Yuan, J., Liu, X., Liu, C., Ang, A. F., Massaro, J., Devine, S. A., Auerbach, S. H., Blusztajn, J. K., Au, R., & Jacques, P. F. (2022) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqac193 · Cited by 61
“The detailed cognitive evaluation methods and case ascertainment procedures have been published elsewhere (21, 22).”
MethodSelf-citationCDH6 and HAGH protein levels in plasma associate with Alzheimer’s disease in APOE ε4 carriers
Ahmad, S., Milan, M. D. C., Hansson, O., Demirkan, A., Agustin, R., Sáez, M. E., Giagtzoglou, N., Cabrera-Socorro, A., Bakker, M. H. M., Ramirez, A., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-65038-5 · Cited by 31
“The levels of CSF AD-related biomarkers (Aβ42, total and phosphorylated tau [t-Tau and p-Tau181]) were analyzed at Amsterdam UMC as part of the routine diagnostic procedure using commercially available kits (Innotest Aβ(1-42), total Tau, phospho-Tau(181 P); Fujirebio, Ghent, Belgium)10,24.”
MethodUsing machine intelligence to uncover Alzheimer’s disease progression heterogeneity
Qorri, B., Tsay, M., Agrawal, A., Au, R., & Gracie, J. (2020) · Exploration of Medicine · doi:10.37349/emed.2020.00026 · Cited by 13
Self-citation
Metadata
- Authors
- Au, R., Piers, R. J., & Lancashire, L.
- Venue
- Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Publisher
- Wiley
- Published
- 2015-06-27
- Volume
- 1
- Issue
- 3
- Pages
- 368-370
- ISSN
- 2352-8729 (ISSN-L)
- OpenAlex
- W1496929074
- Cited by
- 45
- References
- 6
- FWCI
- 1.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Back to the future: Alzheimer's disease heterogeneity revisited. https://app.cochat.ai/papers/10.1016/j.dadm.2015.05.006
- The paper
- Au, R., Piers, R. J., & Lancashire, L. (2015). Back to the future: Alzheimer's disease heterogeneity revisited. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. https://doi.org/10.1016/j.dadm.2015.05.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.